|
|
|
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) |
|
CRVS's Market share relative to its competitors, as of Q1 2025
As of Q1 2025 (Revenue in Millions of $)
Date modified: 2025-07-10T19:44:02+00:00
|
Select the Relationship:
|
|
Select the Category:
|
|
| COMPANY NAME |
REVENUES
12 Months Ending
Q1 2025 |
MARKET SHARE
12 Months
Q1 2025 |
MARKET SHARE
MRQ
Q1 2025 |
MARKET SHARE
A Quarter Before
Q4 2024 |
| Corvus Pharmaceuticals Inc |
0.00 |
0.00% |
0.00 % |
0.00 % |
| Johnson and Johnson |
89,331.00 |
16.49% |
16.54% |
16.10% |
| Merck and Co Inc |
63,922.00 |
11.80% |
11.73% |
11.17% |
| Abbvie Inc |
57,367.00 |
10.59% |
10.08% |
10.80% |
| Sanofi |
49,599.72 |
9.16% |
9.16% |
0.00% |
| Eli Lilly And Company |
49,003.20 |
9.05% |
9.62% |
9.67% |
| Bristol myers Squibb Company |
47,636.00 |
8.79% |
8.46% |
8.82% |
| Novartis Ag |
46,660.00 |
8.61% |
8.61% |
0.00% |
| Astrazeneca Plc |
45,811.00 |
8.46% |
8.46% |
0.00% |
| Takeda Pharmaceutical Company Limited |
29,166.69 |
5.38% |
5.38% |
0.00% |
| Gilead Sciences Inc |
28,735.00 |
5.30% |
5.04% |
5.41% |
| Regeneron Pharmaceuticals Inc |
14,085.70 |
2.60% |
2.29% |
2.71% |
| Vertex Pharmaceuticals Inc |
11,099.70 |
2.05% |
2.09% |
2.08% |
| Organon and Co |
6,294.00 |
1.16% |
1.14% |
1.14% |
| Supernus Pharmaceuticals inc |
668.00 |
0.12% |
0.11% |
0.12% |
| Hutchmed china Limited |
630.20 |
0.12% |
0.12% |
0.00% |
| Madrigal Pharmaceuticals Inc |
317.38 |
0.06% |
0.10% |
0.07% |
| Intercept Pharmaceuticals inc |
288.25 |
0.05% |
0.07% |
0.06% |
| Iovance Biotherapeutics inc |
212.68 |
0.04% |
0.04% |
0.05% |
| Deciphera Pharmaceuticals Inc |
174.91 |
0.03% |
0.03% |
0.03% |
| Rhythm Pharmaceuticals inc |
136.86 |
0.03% |
0.02% |
0.03% |
| Alimera Sciences Inc |
98.09 |
0.02% |
0.02% |
0.02% |
| Zymeworks Inc |
93.38 |
0.02% |
0.02% |
0.02% |
| Y mabs Therapeutics inc |
88.66 |
0.02% |
0.02% |
0.02% |
| Nurix Therapeutics Inc |
88.38 |
0.02% |
0.03% |
0.01% |
| Adc Therapeutics Sa |
75.82 |
0.01% |
0.02% |
0.01% |
| Xoma Royalty Corporation |
42.91 |
0.01% |
0.01% |
0.01% |
| Casi Pharmaceuticals inc |
28.54 |
0.01% |
0.01% |
0.00% |
| Iterum Therapeutics Plc |
14.32 |
0.00% |
0.00% |
0.00% |
| Pliant Therapeutics Inc |
9.85 |
0.00% |
0.00% |
0.00% |
| Affimed N v |
9.27 |
0.00% |
0.00% |
0.00% |
| Adlai Nortye Ltd |
5.00 |
0.00% |
0.00% |
0.00% |
| Salarius Pharmaceuticals inc |
4.70 |
0.00% |
0.00% |
0.00% |
| Nuvalent Inc |
4.23 |
0.00% |
0.00% |
0.00% |
| I mab |
3.89 |
0.00% |
0.00% |
0.00% |
| Bolt Biotherapeutics Inc |
3.64 |
0.00% |
0.00% |
0.00% |
| Reata Pharmaceuticals Inc |
3.15 |
0.00% |
0.02% |
0.00% |
| Oramed Pharmaceuticals Inc |
2.70 |
0.00% |
0.00% |
0.00% |
| Infinity Pharmaceuticals Inc |
2.57 |
0.00% |
0.00% |
0.00% |
| Lumos Pharma Inc |
2.21 |
0.00% |
0.00% |
0.00% |
| Oncternal Therapeutics Inc |
2.16 |
0.00% |
0.00% |
0.00% |
| Ibio inc |
2.11 |
0.00% |
0.00% |
0.00% |
| Actinium Pharmaceuticals Inc |
1.46 |
0.00% |
0.00% |
0.00% |
| Adagene Inc |
0.10 |
0.00% |
0.00% |
0.00% |
| Milestone Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Merrimack Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| 89bio Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Kezar Life Sciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Iveric Bio Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Kinnate Biopharma Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Terns Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Mira Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Inhibitor Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Tyme Technologies Inc. |
0.00 |
0.00% |
0.00% |
0.00% |
| Monopar Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Effector Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Paxmedica Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Phio Pharmaceuticals Corp |
0.00 |
0.00% |
0.00% |
0.00% |
| Nextcure Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Whitehawk Therapeutics Inc |
0.00 |
0.00% |
0.01% |
0.00% |
| Kineta Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Tempest Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Enliven Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| SUBTOTAL |
541,726.41 |
100% |
132,345.97 |
100% |
CRVS's Market share relative to its competitors, as of Q1 2025 within the Major Pharmaceutical Preparations Industry
As of Q1 2025
CRVS's Market share relative to its competitors, as of Q1 2025 within the Healthcare Sector
As of Q1 2025
Note: Market share is calculated based on total revenue. To get a more accurate picture of Corvus Pharmaceuticals Inc's market divisions, geographic dispersion, segments, products, and services, visit Corvus Pharmaceuticals Inc's Business Segment. The list includes publicly traded companies only. More information about the sources of this report can be found here. |
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
